ClinicalTrials.gg
CompletedNCT05876351SolirisUpdated Dec 8, 2025Results posted

Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China

A Phase 3 interventional study of Eculizumab in Atypical Hemolytic Uremic, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 6 sites in China. Open to participants aged 0 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
0 Years to 99 Years
Sex
All
01

Study summary

This is a Phase 3b, open-label, single-arm, multicenter study to evaluate the efficacy and safety of eculizumab in participants with atypical hemolytic uremic syndrome (aHUS) in China

Read the detailed description

This is a Phase 3b, open-label, single-arm, multicenter study to evaluate the efficacy and safety of eculizumab in participants with aHUS in China. The study will be conducted in participants of any age who weigh ≥ 5 kg and who previously have not been treated with complement inhibitors. The study consists of an up to 7-day Screening Period and a 26-week Treatment Period. An 8-week Safety Follow-up Phone Call will be required only for participants who discontinue eculizumab treatment during the study or for participants who will not receive continued access to eculizumab after completing study treatment. Approximately 25 eligible participants in China will be enrolled.

02

Conditions studied

  • Atypical Hemolytic Uremic

Keywords

  • atypical hemolytic uremic
  • aHUS
03

In context

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Any age weighing ≥ 5 kg
  2. Complement treatment naïve with evidence of TMA.
  3. History of aHUS prior to kidney transplant,or persistent evidence of TMA at least 4 days after modifying the regimen.
  4. Among participants with onset of TMA postpartum, persistent evidence of TMA for > 3 days after the day of childbirth
  5. All participants must be vaccinated against N meningitidis if not already vaccinated within the time period of active coverage specified by the vaccine manufacturer.
  6. Participants \< 18 years of age must have been vaccinated against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae according to local vaccination schedule guidelines.
  7. In participants receiving treatment with medications known to cause TMA, persistent evidence of TMA at least 4 days after modifying the excluded medication

Exclusion criteria

Exclusion Criteria:

  1. Known familial or acquired ADAMTS13deficiency (activity \< 5%).
  2. ST-HUS as demonstrated by local guidelines.
  3. Positive direct Coombs test which is indicative of a immune-mediated hemolysis not due to aHUS.
  4. infection, and /or unresolved meningococcal disease
  5. Ongoing sepsis, and / or presence or suspicion of active and untreated systemic infection
  6. Organ transplantation history, and/or Bone marrow transplant/hematopoietic stem cell transplant within 6 months prior to the start of Screening.
  7. Among participants with a kidney transplant, acute kidney dysfunction within 4 weeks of transplant consistent with the diagnosis of acute antibody-mediated rejection.
  8. Among participants without a kidney transplant, history of kidney disease other than aHUS
  9. Identified drug exposure-related HUS, and / or HUS related to vitamin B12 deficiency and / or known genetic defects of cobalamin C metabolism.
  10. History of within 5 years of Screening.
  11. Known systemic sclerosis (scleroderma), systemic lupus erythematosus, or antiphospholipid antibody positivity or syndrome.
  12. Chronic dialysis.
  13. Prior use of complement inhibitors.
  14. Use of tranexamic acid within 7 days prior to the start of Screening.
  15. Other therapies.
  16. Receiving chronic intravenous immunoglobulin (IVIg) within 8 weeks prior to the start of Screening.
  17. Received vasopressors or inotropes within 7 days prior to Screening.
  18. Previously or currently treated with a complement inhibitor.
  19. Has participated in another interventional treatment study or used any experimental therapy.
  20. to any in eculizumab.
  21. Pregnant or breastfeeding.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Eculizumab

    Participants will receive Eculizumab in a single dose vial.

    Drug: Eculizumab

Interventions

  • Weight-based doses of Eculizumab will be administered intravenously as an induction dose followed by maintenance dose at Day 8, 15, or 29 depending on weight; then every 2 or 3 weeks, depending upon weight.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Complete Thrombotic Microangiopathy (TMA) Response

    The criteria for complete TMA response were: 1. Normalization of platelet count (defined as platelet count ≥ 150000/microliter (ul). 2. Normalization of lactate dehydrogenase (LDH, defined as LDH ≤ upper limit of normal \[ULN\]). 3. ≥ 25% improvement in serum creatinine from baseline.

    Time frame: Up to Week 26

Secondary outcomes

  1. Number of Participants With an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. A serious AE (SAE) was defined as any untoward medical occurrence that, at any dose: * resulted in death, * was life-threatening, * required inpatient hospitalization or prolongation of existing hospitalization, * resulted in persistent disability/incapacity, * was a congenital anomaly/birth defect, or * was an important medical event. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Adverse Events' Section.

    Time frame: Up to Week 34

  2. Mean Serum Concentration of Eculizumab

    Time frame: Pre-dose and post-dose at Days 1, 8, 29, 85, and 141; Pre-dose at Day 183

  3. Change From Baseline in Serum Free Complement 5 (C5)

    Time frame: Baseline (Day 1 pre-dose) to Days 1, 8, 29, 85 and 141 (pre-dose and post-dose) and pre-dose at Day 183

  4. Change From Baseline in Serum Total C5

    Time frame: Baseline (Day 1 pre-dose) to Days 1, 8, 29, 85 and 141 (pre-dose and post-dose) and pre-dose at Day 183

  5. Number of Participants With an Anti-drug Antibody (ADA) Response

    An ADA response was defined as a positive ADA sample at any time during the study.

    Time frame: Up to Week 26

  6. Time to Complete TMA Response

    Time to complete TMA response was defined as the time from first infusion to the first time point at which all criteria for complete TMA response was met. The criteria for complete TMA response were: 1. Normalization of platelet count (defined as platelet count ≥ 150000/ul. 2. Normalization of LDH, defined as LDH ≤ ULN). 3. ≥ 25% improvement in serum creatinine from baseline. Participants who did not have a response were censored at the date of last visit or study discontinuation at the time when the analysis was performed.

    Time frame: Up to Week 26

  7. Proportion of Participants On or Off Dialysis at Each Timepoint

    Participants were considered as 'off' dialysis at a specific time point if they were dialysis free for more than 5 days prior to that time point. Participants were considered as 'on' dialysis at a specific time point if they were dialysis free to 5 days or less up prior to that time point.

    Time frame: Baseline and Days 22, 43, 71, 99, 113, 127, 155 and 183

  8. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Each Scheduled Visit

    Expressed in milliliters per minute per 1.73 square meters of body surface area.

    Time frame: Baseline, Days 22, 43, 71, 99, 113, 127, 155 and 183

  9. Proportion of Participants With a Chronic Kidney Disease (CKD) Stage Shift Categorized as "Improved", "Stable", or "Worsened" at Each Scheduled Visit Compared to Baseline

    CKD stage was classified based on the National Kidney Foundation Chronic Kidney Disease Stage where Stage 5 represents the most severe disease and Stage 1 represents the least severe disease. "Improved" excluded participants with Stage 1 at baseline as there was no room for improvement. "Worsened" excludes participants with Stage 5 at baseline as there was no room to worsen.

    Time frame: Baseline to Days 22, 43, 71, 99, 113, 127, 155 and 183

  10. Change From Baseline in Platelets

    Platelet values obtained from the day of a blood transfusion of platelets through 3 days after the transfusion are excluded from all analysis.

    Time frame: Baseline, Days 22, 43, 71, 99, 113, 127, 155, and 183

  11. Change From Baseline in LDH

    Time frame: Baseline, Days 22, 43, 71, 99, 113, 127, 155, and 183

  12. Change From Baseline in Hemoglobin

    Hemoglobin values obtained from the day of a blood transfusion of either whole blood or packed red blood cells through 7 days after the transfusion are excluded from all analysis.

    Time frame: Baseline, Days 22, 43, 71, 99, 113, 127, 155, and 183

07

Results

Posted Dec 8, 2025

Participant flow

Participant flow — Overall Study
MilestoneEculizumab
Started25
Received at least 1 dose of study drug25
Completed22
Not completed3
Withdrew: Other than specified2
Withdrew: Study specific discontinuation criteria1

Outcome measures

PrimaryPercentage of Participants With a Complete Thrombotic Microangiopathy (TMA) Response

The criteria for complete TMA response were: 1. Normalization of platelet count (defined as platelet count ≥ 150000/microliter (ul). 2. Normalization of lactate dehydrogenase (LDH, defined as LDH ≤ upper limit of normal \[ULN\]). 3. ≥ 25% improvement in serum creatinine from baseline.

Time frame:
Up to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Complete Thrombotic Microangiopathy (TMA) Response
percentage of participantsEculizumab
Percentage of Participants With a Complete Thrombotic Microangiopathy (TMA) Response64.0 ± 42.5
SecondaryNumber of Participants With an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. A serious AE (SAE) was defined as any untoward medical occurrence that, at any dose: * resulted in death, * was life-threatening, * required inpatient hospitalization or prolongation of existing hospitalization, * resulted in persistent disability/incapacity, * was a congenital anomaly/birth defect, or * was an important medical event. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Adverse Events' Section.

Time frame:
Up to Week 34
Reported as:
Count of participants · Participants
Number of Participants With an Adverse Event (AE)
ParticipantsEculizumab
Any AE24
Any SAE8
SecondaryMean Serum Concentration of Eculizumab
Time frame:
Pre-dose and post-dose at Days 1, 8, 29, 85, and 141; Pre-dose at Day 183
Reported as:
Geometric mean · micrograms per milliliter (ug/mL)
Mean Serum Concentration of Eculizumab
micrograms per milliliter (ug/mL)Eculizumab
Day 1: Pre-dose4.690 ± 0.00
Day 1: Post-dose373.423 ± 47.59
Day 8: Pre-dose153.190 ± 69.69
Day 8: Post-dose498.262 ± 41.18
Day 29: Pre-dose353.726 ± 36.96
Day 29: Post-dose727.862 ± 32.22
Day 85: Pre-dose360.070 ± 43.89
Day 85: Post-dose728.624 ± 42.04
Day 141: Pre-dose433.737 ± 41.32
Day 141: Post-dose883.675 ± 38.74
Day 183: Pre-dose434.739 ± 38.66
SecondaryChange From Baseline in Serum Free Complement 5 (C5)
Time frame:
Baseline (Day 1 pre-dose) to Days 1, 8, 29, 85 and 141 (pre-dose and post-dose) and pre-dose at Day 183
Reported as:
Mean · ug/mL
Change From Baseline in Serum Free Complement 5 (C5)
ug/mLEculizumab
Day 1: Post-dose-79.8842 ± 17.5197
Day 8: Pre-dose-79.6539 ± 17.8589
Day 8: Post-dose-79.6636 ± 17.8610
Day 29: Pre-dose-80.4277 ± 17.1241
Day 29: Post-dose-80.4284 ± 17.1241
Day 85: Pre-dose-80.0632 ± 17.3489
Day 85: Post-dose-80.0632 ± 17.3489
Day 141: Pre-dose-80.0625 ± 17.3485
Day 141: Post-dose-80.0632 ± 17.3489
Day 183: Pre-dose-80.0632 ± 17.3489
SecondaryChange From Baseline in Serum Total C5
Time frame:
Baseline (Day 1 pre-dose) to Days 1, 8, 29, 85 and 141 (pre-dose and post-dose) and pre-dose at Day 183
Reported as:
Mean · ug/mL
Change From Baseline in Serum Total C5
ug/mLEculizumab
Day 1: Post-dose-12.0267 ± 6.1396
Day 8: Pre-dose37.9293 ± 21.3162
Day 8: Post-dose40.2831 ± 23.0175
Day 29: Pre-dose65.9100 ± 25.0734
Day 29: Post-dose64.4783 ± 22.7695
Day 85: Pre-dose71.2418 ± 25.7350
Day 85: Post-dose66.5267 ± 26.7232
Day 141: Pre-dose71.8284 ± 25.3689
Day 141: Post-dose67.0693 ± 23.1231
Day 183: Pre-dose78.5497 ± 27.1158
SecondaryNumber of Participants With an Anti-drug Antibody (ADA) Response

An ADA response was defined as a positive ADA sample at any time during the study.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With an Anti-drug Antibody (ADA) Response
ParticipantsEculizumab
Number of Participants With an Anti-drug Antibody (ADA) Response0
SecondaryTime to Complete TMA Response

Time to complete TMA response was defined as the time from first infusion to the first time point at which all criteria for complete TMA response was met. The criteria for complete TMA response were: 1. Normalization of platelet count (defined as platelet count ≥ 150000/ul. 2. Normalization of LDH, defined as LDH ≤ ULN). 3. ≥ 25% improvement in serum creatinine from baseline. Participants who did not have a response were censored at the date of last visit or study discontinuation at the time when the analysis was performed.

Time frame:
Up to Week 26
Reported as:
Median · days
Time to Complete TMA Response
daysEculizumab
Time to Complete TMA Response75.0 (22.0 to NA)
SecondaryProportion of Participants On or Off Dialysis at Each Timepoint

Participants were considered as 'off' dialysis at a specific time point if they were dialysis free for more than 5 days prior to that time point. Participants were considered as 'on' dialysis at a specific time point if they were dialysis free to 5 days or less up prior to that time point.

Time frame:
Baseline and Days 22, 43, 71, 99, 113, 127, 155 and 183
Reported as:
Number · proportion of participants
Proportion of Participants On or Off Dialysis at Each Timepoint
proportion of participantsEculizumab
Baseline: On Dialysis0.440 (0.244 to 0.651)
Baseline: Off Dialysis0.560 (0.349 to 0.756)
Day 22: On Dialysis0.261 (0.102 to 0.484)
Day 22: Off Dialysis0.739 (0.516 to 0.898)
Day 43: On Dialysis0.235 (0.068 to 0.499)
Day 43: Off Dialysis0.765 (0.501 to 0.932)
Day 71: On Dialysis0.211 (0.061 to 0.456)
Day 71: Off Dialysis0.789 (0.544 to 0.939)
Day 99: On Dialysis0.176 (0.038 to 0.434)
Day 99: Off Dialysis0.824 (0.566 to 0.962)
Day 113: On Dialysis0.167 (0.036 to 0.414)
Day 113: Off Dialysis0.833 (0.586 to 0.964)
Day 127: On Dialysis0.111 (0.014 to 0.347)
Day 127: Off Dialysis0.889 (0.653 to 0.986)
Day 155: On Dialysis0.167 (0.036 to 0.414)
Day 155: Off Dialysis0.833 (0.586 to 0.964)
Day 183: On Dialysis0.167 (0.036 to 0.414)
Day 183: Off Dialysis0.833 (0.586 to 0.964)
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Each Scheduled Visit

Expressed in milliliters per minute per 1.73 square meters of body surface area.

Time frame:
Baseline, Days 22, 43, 71, 99, 113, 127, 155 and 183
Reported as:
Mean · mL/min/1.73^2
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Each Scheduled Visit
mL/min/1.73^2Eculizumab
Day 2239.82 ± 50.83
Day 4332.72 ± 44.75
Day 7140.33 ± 47.38
Day 9937.53 ± 47.17
Day 11335.88 ± 45.38
Day 12735.85 ± 48.01
Day 15543.33 ± 49.32
Day 18336.29 ± 44.21
SecondaryProportion of Participants With a Chronic Kidney Disease (CKD) Stage Shift Categorized as "Improved", "Stable", or "Worsened" at Each Scheduled Visit Compared to Baseline

CKD stage was classified based on the National Kidney Foundation Chronic Kidney Disease Stage where Stage 5 represents the most severe disease and Stage 1 represents the least severe disease. "Improved" excluded participants with Stage 1 at baseline as there was no room for improvement. "Worsened" excludes participants with Stage 5 at baseline as there was no room to worsen.

Time frame:
Baseline to Days 22, 43, 71, 99, 113, 127, 155 and 183
Reported as:
Number · proportion of participants
Proportion of Participants With a Chronic Kidney Disease (CKD) Stage Shift Categorized as "Improved", "Stable", or "Worsened" at Each Scheduled Visit Compared to Baseline
proportion of participantsEculizumab
Day 22: Improved0.545 (0.322 to 0.756)
Day 22: Stable0.455 (0.244 to 0.678)
Day 22: Worsened0 (0 to 0.410)
Day 43: Improved0.688 (0.413 to 0.890)
Day 43: Stable0.313 (0.110 to 0.587)
Day 43: Worsened0 (0 to 0.602)
Day 71: Improved0.722 (0.465 to 0.903)
Day 71: Stable0.278 (0.097 to 0.535)
Day 71: Worsened0 (0 to 0.522)
Day 99: Improved0.750 (0.476 to 0.927)
Day 99: Stable0.250 (0.073 to 0.524)
Day 99: Worsened0 (0 to 0.522)
Day 113: Improved0.765 (0.501 to 0.932)
Day 113: Stable0.235 (0.068 to 0.499)
Day 113: Worsened0 (0 to 0.459)
Day 127: Improved0.765 (0.501 to 0.932)
Day 127: Stable0.235 (0.068 to 0.499)
Day 127: Worsened0 (0 to 0.459)
Day 155: Improved0.875 (0.617 to 0.984)
Day 155: Stable0.125 (0.016 to 0.383)
Day 155: Worsened0 (0 to 0.522)
Day 183: Improved0.824 (0.566 to 0.962)
Day 183: Stable0.176 (0.038 to 0.434)
Day 183: Worsened0 (0 to 0.522)
SecondaryChange From Baseline in Platelets

Platelet values obtained from the day of a blood transfusion of platelets through 3 days after the transfusion are excluded from all analysis.

Time frame:
Baseline, Days 22, 43, 71, 99, 113, 127, 155, and 183
Reported as:
Mean · 10^9 platelets/liter (L)
Change From Baseline in Platelets
10^9 platelets/liter (L)Eculizumab
Day 2276.5 ± 117.7
Day 4365.5 ± 90.1
Day 7171.3 ± 97.9
Day 9979.4 ± 68.1
Day 11360.1 ± 82.7
Day 12761.8 ± 86.1
Day 15576.8 ± 98.2
Day 18380.3 ± 98.0
SecondaryChange From Baseline in LDH
Time frame:
Baseline, Days 22, 43, 71, 99, 113, 127, 155, and 183
Reported as:
Mean · microkatal per liter (ukat/L)
Change From Baseline in LDH
microkatal per liter (ukat/L)Eculizumab
Day 22-9.445 ± 12.459
Day 43-6.147 ± 10.175
Day 71-7.083 ± 10.099
Day 99-5.861 ± 8.356
Day 113-5.769 ± 8.041
Day 127-5.444 ± 8.314
Day 155-5.848 ± 8.478
Day 183-5.680 ± 8.172
SecondaryChange From Baseline in Hemoglobin

Hemoglobin values obtained from the day of a blood transfusion of either whole blood or packed red blood cells through 7 days after the transfusion are excluded from all analysis.

Time frame:
Baseline, Days 22, 43, 71, 99, 113, 127, 155, and 183
Reported as:
Mean · grams per liter (g/L)
Change From Baseline in Hemoglobin
grams per liter (g/L)Eculizumab
Day 2217.0 ± 18.3
Day 4325.7 ± 20.1
Day 7130.5 ± 22.6
Day 9930.3 ± 19.3
Day 11329.8 ± 17.8
Day 12725.2 ± 16.4
Day 15530.5 ± 14.9
Day 18336.2 ± 15.8

Adverse events

Collected over Up to Week 34. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eculizumab0/25 (0%)8/25 (32%)24/25 (96%)
Most frequent serious events
Most frequent serious events
EventEculizumab
PneumoniaInfections and infestations2/25
Bacterial infectionInfections and infestations1/25
Clostridium difficile infectionInfections and infestations1/25
InfectionInfections and infestations1/25
Rotavirus infectionInfections and infestations1/25
RetchingGastrointestinal disorders1/25
Upper gastrointestinal haemorrhageGastrointestinal disorders1/25
Hepatic function abnormalHepatobiliary disorders1/25
Synovial cystMusculoskeletal and connective tissue disorders1/25
Most frequent other events
Showing 10 of 17
Most frequent other events
EventEculizumab
HyperkalaemiaMetabolism and nutrition disorders7/25
Upper respiratory tract infectionInfections and infestations5/25
VomitingGastrointestinal disorders5/25
Respiratory tract infectionInfections and infestations4/25
Hepatic function abnormalHepatobiliary disorders4/25
InfectionInfections and infestations3/25
HyperphosphataemiaMetabolism and nutrition disorders3/25
PyrexiaGeneral disorders3/25
BronchitisInfections and infestations2/25
InfluenzaInfections and infestations2/25

Baseline characteristics

Full Analysis Set: Included all participants who received at least 1 dose of study intervention and had at least 1 efficacy assessment post first dose.

Age, Continuous
Age, Continuous(years)Eculizumab
Mean23.40 ± 15.95
Age, Customized
Age, Customized(Participants)Eculizumab
In utero0
Preterm newborn infants (gestational age < 37 wks)0
Newborns (0-27 days)0
Infants and toddlers (28 days-23 months)2
Children (2-11 years)7
Adolescents (12-17 years)2
Adults (18-64 years)14
From 65-84 years0
85 years and over0
Sex: Female, Male
Sex: Female, Male(Participants)Eculizumab
Female6
Male19
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Eculizumab
Hispanic or Latino0
Not Hispanic or Latino24
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Eculizumab
American Indian or Alaska Native0
Asian25
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

6 sites
  • Research Site
    Beijing, 100034, China
  • Research Site
    Beijing, 100045, China
  • Research Site
    Changsha, 410007, China
  • Research Site
    Qingdao, 110016, China
  • Research Site
    Taiyuan, 030012, China
  • Research Site
    Wuhan, 430030, China
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in May 2025, 21 months.

Results were first posted in Dec 2025, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2023
First posted
May 25, 2023
StartActual
Jul 14, 2023
Primary completionActual
May 7, 2025
CompletionActual
May 7, 2025
Results first posted
Dec 8, 2025
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05876351
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
May 25, 2023
Start date
Jul 14, 2023
Primary completion
May 7, 2025
Completion
May 7, 2025
Results posted
Dec 8, 2025
Last update
Dec 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion